Superworth

Femasys price to sales ratio FEMY

Market value divided by revenue over the last twelve months, since 2022.

Today, Nov 2, 2026
4.8×
5-year median
15.4×
Against its 5-year history
4th
percentile: 0 is its lowest day, 100 its highest
5-year range
2.9× to 40.4×
Peer median
0.9×

Femasys' price to sales ratio is 4.8× as of Nov 2, 2026.

That is below its 5-year median of 15.4×, lower than on 96% of days in the last 5 years.

Over that time it ranged from 2.9× in Aug 2026 to 40.4× in Mar 2024.

The median for 3 medical instruments and supplies stocks of a similar size is 0.9×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far4.8×2.9×18.5×
202520.1×6.0×29.8×
202420.5×15.4×40.4×
202319.3×3.9×37.6×
20228.7×8.7×25.6×

Against its peers

Companies in Medical - Instruments & Supplies nearest Femasys' size, closest first, today.

CompanyPrice to sales ratio
FEMYFemasys4.8×
NEPHNephros1.7×
APTAlpha Pro Tech0.9×
KEQUKewaunee Scientific0.3×
Peer median0.9×

Where Femasys ranks

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Femasys

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.